Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer

BACKGROUND: Six months of adjuvant chemotherapy is regarded as the standard of care for patients with stage III colon cancer. However, whether longer treatment can improve prognosis has not been fully investigated. We conducted a phase III study comparing 6 and 12 months of adjuvant capecitabine che...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Clin Oncol
Glavni autori: Suto, Takeshi, Ishiguro, Megumi, Hamada, Chikuma, Kunieda, Katsuyuki, Masuko, Hiroyuki, Kondo, Ken, Ishida, Hideyuki, Nishimura, Genichi, Sasaki, Kazuaki, Morita, Takayuki, Hazama, Shoichi, Maeda, Koutarou, Mishima, Hideyuki, Ike, Hideyuki, Sadahiro, Sotaro, Sugihara, Kenichi, Okajima, Masazumi, Saji, Shigetoyo, Sakamoto, Junichi, Tomita, Naohiro
Format: Artigo
Jezik:Inglês
Izdano: Springer Japan 2017
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486458/
https://ncbi.nlm.nih.gov/pubmed/28078540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-016-1083-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items